OREANDA-NEWS. December 12, 2013. World-class investigators affiliated with US Oncology Research participated in studies that will be presented Dec. 10-14 at the Henry B. Gonzales Convention Center during the 2013 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.

Devchand Paul, D.O., Ph.D., F.A.C.P., breast oncologist with Rocky Mountain Cancer Centers, a practice affiliated with The US Oncology Network and US Oncology Research, is lead author of a study titled, Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy.

Dr. Paul will present study findings during an oral presentation on Thursday, Dec. 12 from 11:00-11:15 a.m., providing an in-depth look at letrozole plus dasatinib as first-line aromatase inhibitor treatment for hormone receptor positive, metastatic breast cancer, in postmenopausal women. c-Src is a tyrosine kinase involved in breast cancer invasion, proliferation, survival, and is involved in endocrine therapy resistance. Dasatinib is an oral c-Src inhibitor.

"This small, preliminary report is exciting in that it potentially lays the foundation for future studies in preventing or reversing resistance to aromatase inhibitor therapy," said Dr. Paul.

Additionally, more than 40 investigators affiliated with US Oncology Research participated in the studies listed below that will be featured at the conference. For more information or to interview an investigator, contact US Oncology Research Public Relations Manager, Claire Crye at 281-863-6783.